Cargando…

RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses

Blast-phase chronic myeloid leukemia (BP-CML) is associated with additional chromosomal aberrations, RUNX1 mutations being one of the most common. Tyrosine kinase inhibitor therapy has only limited efficacy in BP-CML, and characterization of more defined molecular subtypes is warranted in order to d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adnan Awad, Shady, Dufva, Olli, Ianevski, Aleksandr, Ghimire, Bishwa, Koski, Jan, Maliniemi, Pilvi, Thomson, Daniel, Schreiber, Andreas, Heckman, Caroline A., Koskenvesa, Perttu, Korhonen, Matti, Porkka, Kimmo, Branford, Susan, Aittokallio, Tero, Kankainen, Matti, Mustjoki, Satu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024199/ https://www.ncbi.nlm.nih.gov/pubmed/32782381 http://dx.doi.org/10.1038/s41375-020-01011-5

Ejemplares similares

Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia
por: Hohtari, Helena, et al.
Publicado: (2022)

P1228: GENOME-WIDE CRISPR-CAS9 SCREENING IDENTIFIES THERAPEUTIC TARGETS FOR MATURE T-CELL MALIGNANCIES
por: Timonen, Sanna, et al.
Publicado: (2023)

Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation
por: Adnan Awad, Shady, et al.
Publicado: (2022)

Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Hohtari, Helena, et al.
Publicado: (2022)

Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets
por: Adnan-Awad, Shady, et al.
Publicado: (2020)

Chronic myeloid leukemia patients’ adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians
por: Kekäle, Meri, et al.
Publicado: (2014)

STAT3 activation in large granular lymphocyte leukemia is associated with cytokine signaling and DNA hypermethylation
por: Kim, Daehong, et al.
Publicado: (2021)

Real‐world experience of novel multiple myeloma treatments in a large, single‐center cohort in Finland
por: Loponen, Heidi, et al.
Publicado: (2023)

Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
por: Malani, Disha, et al.
Publicado: (2022)

Patient-tailored design for selective co-inhibition of leukemic cell subpopulations
por: Ianevski, Aleksandr, et al.
Publicado: (2021)

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing
por: Pietarinen, P O, et al.
Publicado: (2015)

An immunity and pyroptosis gene-pair signature predicts overall survival in acute myeloid leukemia
por: Kong, Weikaixin, et al.
Publicado: (2022)

Dasatinib promotes Th1-type responses in granzyme B expressing T-cells
por: Kreutzman, Anna, et al.
Publicado: (2014)

Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2020)

SynergyFinder 2.0: visual analytics of multi-drug combination synergies
por: Ianevski, Aleksandr, et al.
Publicado: (2020)

Fully-automated and ultra-fast cell-type identification using specific marker combinations from single-cell transcriptomic data
por: Ianevski, Aleksandr, et al.
Publicado: (2022)

SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples
por: Ianevski, Aleksandr, et al.
Publicado: (2022)

Somatic STAT3 mutations in CD8(+) T cells of healthy blood donors carrying human T-cell leukemia virus type 2
por: Kim, Daehong, et al.
Publicado: (2021)

SynergyFinder: a web application for analyzing drug combination dose–response matrix data
por: Ianevski, Aleksandr, et al.
Publicado: (2017)

SynergyFinder: a web application for analyzing drug combination dose–response matrix data
por: Ianevski, Aleksandr, et al.
Publicado: (2020)

Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
por: Dufva, Olli, et al.
Publicado: (2018)

IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia
por: Huuhtanen, Jani, et al.
Publicado: (2022)

Enlarged Memory T-Cell Pool and Enhanced Th1-Type Responses in Chronic Myeloid Leukemia Patients Who Have Successfully Discontinued IFN-α Monotherapy
por: Ilander, Mette, et al.
Publicado: (2014)

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
por: Hjorth-Hansen, Henrik, et al.
Publicado: (2015)

Comparison of Structural and Short Variants Detected by Linked-Read and Whole-Exome Sequencing in Multiple Myeloma
por: Kumar, Ashwini, et al.
Publicado: (2021)

SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy
por: Ianevski, Aleksandr, et al.
Publicado: (2020)

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia
por: El Missiry, Mohamed, et al.
Publicado: (2017)

T and NK cell abundance defines two distinct subgroups of renal cell carcinoma
por: Lee, Moon Hee, et al.
Publicado: (2022)

Pseudoexons provide a mechanism for allele-specific expression of APC in familial adenomatous polyposis
por: Nieminen, Taina T., et al.
Publicado: (2016)

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
por: Yadav, Bhagwan, et al.
Publicado: (2014)

Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL
por: Hohtari, Helena, et al.
Publicado: (2019)

Hemophagocytic Lymphohistiocytosis in RUNX1::RUNX1T1 Positive AML with Blast Count Below 20%
por: Huang, Xingqin, et al.
Publicado: (2023)

Ponatinib‐induced ichthyosiform eruption
por: Kluger, Nicolas, et al.
Publicado: (2021)

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity
por: Schiffer, Charles A., et al.
Publicado: (2016)

Somatic mutations and T-cell clonality in patients with immunodeficiency
por: Savola, Paula, et al.
Publicado: (2019)

Breeze 2.0: an interactive web-tool for visual analysis and comparison of drug response data
por: Potdar, Swapnil, et al.
Publicado: (2023)

The impact of RNA sequence library construction protocols on transcriptomic profiling of leukemia
por: Kumar, Ashwini, et al.
Publicado: (2017)

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2023)

MATLIGN: a motif clustering, comparison and matching tool
por: Kankainen, Matti, et al.
Publicado: (2007)

POCO: discovery of regulatory patterns from promoters of oppositely expressed gene sets
por: Kankainen, Matti, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_b5vsefv834ds6i0dkb32hba93o